Glaukos (GKOS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 4. ...

Glaukos Corporation (GKOS) has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutical company. It is ...

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry's 5.4% growth. The S&P 500 Index has also increased 15% in the same time frame. Glaukos, with a market capitalization of $7.1 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 3 ...

Glaukos (GKOS) has witnessed strong momentum in the year-to-date period. Shares of the company have surged 63.5% compared with 9.1% growth of the industry. The S&P 500 composite has risen 17.4% during the said time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutical company. It is focused on the ...

For the quarter ended June 2024, Glaukos (GKOS) reported revenue of $95.69 million, up 19% over the same period last year. EPS came in at -$0.52, compared to -$0.55 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $88.41 million, representing a surprise of +8.24%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.52. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they com ...

Glaukos Corporation (GKOS) reported second-quarter 2024 adjusted loss of 52 cents per share, in line with the Zacks Consensus Estimate. The figure was narrower than the year-ago quarter's adjusted loss of 55 cents per share. The GAAP loss per share was $1.06 compared with the prior-year quarter's reported loss of 68 cents. Revenue Details Glaukos registered revenues of $95.7 million in the second quarter, up 19% year over year on a reported basis and 20% at constant currency (cc). The figure also surpassed ...

Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.58 per share when it actually produced a loss of $0.70, delivering a surprise of -20.69%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Glaukos, which belongs t ...

Glaukos (GKOS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the ...

With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Glaukos (GKOS) witnessed strong momentum in the year-to-date period. Shares of the company surged 51.9% compared with 4.3% growth of the industry. The S&P 500 Composite has risen 14.3% during the same time frame. Image Source: Zacks Investment Research Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutica ...

Glaukos is witnessing an upward trend in its stock price, prompted by its strength in its flagship iStent. The optimism led by a solid first-quarter 2024 performance and potential in its international market are expected to contribute further. However, stiff competition and pipeline setbacks continue to concern the company. Ecolab's shares have rallied 32.7% against the industry's 12.8% decline in the past year. Stiff Competition: Glaukos' competitors include medical companies, academic and research institu ...